Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Haywire,
I’m happy you reminded me.
Yes , at present my prediction on the FDA’s concerns( not mine !) on the issue raised, has not resulted in any significant impact to those therapies and as such, presently my opinion has proven incorrect.
Always happy to stand corrected .
How is it , ahead of time your repeated posting of maybe 3 patients being dosed , ( very specific) and now the company confirming the same are so precise?
Congratulations on being spot on !!
AIMO
HT,
I’ve previously answered you !… No.
I think Dhub mentioned he was . Maybe he can help you with whatever related question you have.
Probably you could give Shicky some more details with respect to his/her question as a knowledgeable LTH.
AIMO
Shicky,
Check out C4X and their recent RNS’s should you want to learn more on the de-listing and private company theme.
I’m not suggesting Hemo’ will , although many here intimating within recent posts, the possibility and logic to do so.
Maybe ask one of those posters for more details.
AIMO
Chaps,
Unlike others here, I’m very happy to answer your question.
My opinion on the timing of the previous placing was based on two aspects;
One, company announcements & two , the so called LTH’s (a specific group) postings and predictions on this board.
That same specific group are now making noises ( at least three recent and separate posts) of the possibility of de-listing and the company going private!
It’s interesting others have now recognized the MO of said same group.
Any other questions?
AIMO
HK,
Why did you specifically mention a company who recently de-listed , when it had no relevance to the point you were communicating within your earlier post ?
Some may have perceived as a threat of such action , particularly if you were to believe JHFH’s conviction of who you really are !
Hopefully he’s wrong.
AIMO
HK,
Yeah, let’s stop the speculation !
We should all just wait to find out how the company is going to raise/secure the significant funds it says it needs.
( Company RNS ,…fact).
As a person keen on quoting stats, maybe you could work out for all to consider;
-of the previous funding rounds what percentage were none diluting to the relevant holders at raise.
I suspect a stat your not so keen to share !
AIMO
Isn’t it interesting, some might consider telling, how over a very short period, the ramp gang are now falling over themselves to claim a dilutive placing’s a really good thing, when a day or two prior, there was not a cat in hell’s chance!
Mr I , if you want to turn stones over and potentially expose individuals for having inside information, i’d suggest you look at such posters!.. one in particular.
AIMO
Hiki,
Why would funding most likely be dilutive with such a bright future.
JFH has told us all Hemo’ have a cure for all viruses and cancer, are u saying given that , Hemo’ can’t get none dilutive funding?
Pick an argument and think it through before u post !
AIMO
JFH,
What i find disgusting are those that knowingly deceive, attempting to convince the less informed to invest …ring any bells!?
-The mCap is incorrect and MUST re-rate.
-There is no possibility of dilutive funding.
-There is no risk remaining, now clinical.
-The only reason for languishing SP,..shorter’s.
-Hemo’ HAVE a cure for all viruses and cancer.
-The ongoing FDA investigations into Car-T risks, could not possibly have any ramifications for Hemo’
the list is as long as your posts…very long!
Fortunately whatever’s posted here will have very little if any impact to the SP, the company and the outcome.
The bigger market determines the direction of travel and that’s professional investors with informed insight and not biased, deceitful amateurs.
As I’ve previously mentioned.
I think you are already certain of what’s coming!?
In anticipation, your simply pushing a false narrative on traders/shorter’s…ANYTHING other than the true reasons.
Why? to try and deflect criticism when it happens.
I guess understandable as it’s,Just For Hemo !
AIMO
Ps You may as well post your apology in advance.
JFH,
I’m looking forward to both yours and Haywain’s public apology on this board when you’re proven incorrect!
Hopefully I’ll be somewhere with wifi to fully enjoy .
AIMO
In your case, incorrect again ! CH Mr 95% !
Haywain,
How could the FDA hold Hemo’s solution when presently they have no definitive conclusion on this particular risk with Car-T ?
Don’t be so obtuse and patronizing to the many others here less informed!
Let’s see what the FDA March meeting concludes.
I presume you will offer the same as i , a full and public apology should you be wrong and new FDA requirements become apparent?
AIMO
Haywain,
We both know the FDA can only asses on the present understanding and of course presently, all is satisfactory.
To suggest confidence it can ONLY remain the case is disingenuous.
Big Pharma have expressed concern but you don’t’.
Who should investors believe?
AIMO
Ps.
I note your climb down on Auto v’s Allo’.
Haywain,
You state:
“The risk for the stated oncogenic potential of autologous CAR-t associated with DNA integration from the viral vector is as much of a risk in autologous CAR-T as it is in allogenic CAR-T but with allogenic presenting additional challenges that must be addressed due to the fact that the cell is not isolated from the patient”
…and yet the FDA position is :
“The FDA is specifically applying the perceived risk of T-cell malignancies to autologous CAR-Ts without touching on allogeneic, or “off-the-shelf” candidates, which also use the viral vectors”
I think I’ll stick with the FDA’s unbiased and present stance!
Let’s see how things progress with the FDA , March meetings and subsequent findings/recommendations.
As with my wager on funding with JFH , I’ll apply the same ( full and public apology), in the event there are no new FDA requirements arising for Hemo’ on this specific point.
Time will tell.
AIMO